Naevocyte triggering by recombinant human growth hormone

The Journal of Pathology
G E PiérardJ P Bourguignon

Abstract

The influence of growth hormone and insulin-like growth factor I on human melanocytes is being increasingly recognized. Clinical evidence has shown that when recombinant human growth hormone (hGH) is administered to children of short stature, the growth of melanocytic naevi is boosted. This study was conducted on 56 hGH-triggered naevi and nine similar lesions excised before or after hGH therapy for hypopituitarism and Turner's syndrome. A series of 40 naevi excised from age-matched healthy children served as controls. Atypicality of naevocytes was investigated using image analysis, AgNOR counts, immunohistochemistry (HMB-45, NKI-C3, Ki-67, anti-bcl-2-oncoprotein), and DNA flow cytometry. The data associate hGH treatment with anisokaryosis and increased AgNOR and Ki-67 counts in naevocytes. The same cells also show abnormal patterns of HMB-45 immunolabelling. These indications of naevocyte activation were not suggestive of malignant transformation. hGH-triggered melanocytomas should be added to the list of atypical melanocytic naevi. The long-term evolution of these lesions remains unknown and the potential risk of malignant transformation awaits careful evaluation.

References

Oct 11, 1992·Journal of the American Academy of Dermatology·D L EllisL B Nanney
Dec 1, 1992·The American Journal of Dermatopathology·M G FlemingA G Candel
Dec 1, 1991·The American Journal of Dermatopathology·H G SkeltonJ H Graham
Jan 1, 1991·Acta Paediatrica Scandinavica. Supplement·P ChatelainJ Saez
Mar 1, 1991·The Journal of Investigative Dermatology·G ScottR Halaban
Oct 1, 1990·The American Journal of Dermatopathology·G LeitingerH Kerl
Feb 1, 1988·The American Journal of Dermatopathology·G Goovaerts, N Buyssens
Jun 1, 1985·Archives of Dermatology·A W KopfM Levenstein
May 1, 1983·Cancer Genetics and Cytogenetics·E ThermanD A Buchler
Jan 1, 1995·Dermatology : International Journal for Clinical and Investigative Dermatology·G E PiérardJ E Arrese
Feb 1, 1995·The American Journal of Dermatopathology·M Tronnier, H H Wolff
Feb 1, 1995·The American Journal of Dermatopathology·F FogtS R Tahan
Feb 1, 1995·The American Journal of Dermatopathology·L CerroniH Kerl
Dec 1, 1994·The American Journal of Dermatopathology·B FazaaG E Piérard
Jun 1, 1994·The American Journal of Dermatopathology·C Piérard-Franchimont, G E Piérard
Aug 1, 1994·The American Journal of Dermatopathology·M G FlemingL H Graf
Jun 12, 1993·Lancet·J P BourguignonC Franchimont

❮ Previous
Next ❯

Citations

Feb 18, 2004·Journal of Endocrinological Investigation·M BidlingmaierC J Strasburger
Jul 19, 2011·Expert Opinion on Biological Therapy·Claudine Piérard-FranchimontPascale Quatresooz
May 21, 2008·International Journal of Cosmetic Science·P QuatresoozG E Piérard
Apr 10, 2014·BioMed Research International·Trinh Hermanns-Lê, Sébastien Piérard
Jan 6, 2012·Arquivos brasileiros de endocrinologia e metabologia·Flavio Moutinho Souza, Paulo Ferrez Collett-Solberg
Apr 21, 2004·Journal of the American Academy of Dermatology·Eve J LowensteinSharon A Glick
Jul 20, 2002·Current Opinion in Pediatrics·Dorothy I Shulman
May 14, 1999·The Journal of Clinical Endocrinology and Metabolism·S R EdmondsonG A Werther
Dec 13, 2003·Endocrine Reviews·Stephanie R EdmondsonChristopher J Wraight

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.